Publications by authors named "S E Faustini"

: Generalised immune dysfunction in chronic kidney disease, especially in patients requiring haemodialysis (HD), significantly enhances the risk of severe infections. Vaccine-induced immunity is typically reduced in HD populations. The SARS-CoV-2 pandemic provided an opportunity to examine the magnitude and functionality of antibody responses in HD patients to a previously unencountered antigen-Spike (S)-glycoprotein-after vaccination with different vaccine platforms (viral vector (VV); mRNA (mRV)).

View Article and Find Full Text PDF

Objectives: Vitamin D has a role in the innate immunity against pathogens and is also involved in mechanisms for reducing inflammation. VD deficiency (VDD) may increase COVID-19 infection susceptibility, however research is limited on the association between VDD and COVID-19 symptom prevalence and duration. The study aimed to determine whether VDD is a risk factor for the presence and extended duration of COVID-19 symptoms.

View Article and Find Full Text PDF

Aim: The EarLy Surveillance for Autoimmune (ELSA) study aims to explore the feasibility and acceptability of UK paediatric general population screening for type 1 diabetes.

Methods: We aim to screen 20,000 children aged 3-13 years for islet-specific autoantibodies through dried blood spot sample collection at home, hospital or community settings. Children with two or more autoantibodies are offered metabolic staging via oral glucose challenge testing.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on short- and long-term antibody responses to pneumococcal vaccines in HIV-infected adults, comparing two types of vaccines: Pneumovax-23 (PPV) and Prevenar-13 (PCV).
  • A subgroup of 152 participants from a larger study had their antibody levels measured before and after vaccination, with ongoing assessments for four years. Results indicated that those vaccinated with PCV had a higher likelihood of achieving the World Health Organization's antibody threshold than those who received PPV.
  • Specifically, 54% of PCV recipients reached the target after one dose compared to 33% with PPV, and this advantage continued with booster doses, showing better cumulative rates
View Article and Find Full Text PDF